Pathalys Pharma
Biopharma, Biotechnology
Founded in 1/1/21
Raleigh, North Carolina, United States
For Profit
About Pathalys Pharma
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. Pathalys' initial focus will be on improving treatment for secondary hyperparathyroidism, which is an unmet need (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all of the parathyroid glands to swell and become hyperactive, producing an excessive amount of parathyroid hormone (PTH).
Company Metrics
- Employees: 1-10
- Monthly Visits: 8905
- Tech Stack: None active products
Financial Information
- Estimated Revenue:
- Total Funding: 161000000 USD
- Last Funding: 150000000 USD (Series A)
- Funding Status: Early Stage Venture
Technology Stack
Pathalys Pharma actively uses None products in their tech stack.
Market Presence
Industries: Biopharma, Biotechnology
Headquarters: Raleigh, North Carolina, United States
Leadership
- Theodore Danoff - CMO & VP, Clinical Development LinkedIn
Employees
- Neal Fowler - Chief Executive Officer (LinkedIn)
- Patrick Treanor - Chief Operating Officer (LinkedIn)